Schizophrenia is sometimes considered one of the most devastating of mental illnesses because its onset is early in a patient’s life and its symptoms can be destructive to the patient, the family, and friends. Schizophrenia affects 1 in 100 people at some point during their lives, and while there is no cure, it is treatable with antipsychotic medications. According to the Clinical Antipsychotic Trials for Interventions Effectiveness (CATIE), about 74% of the patients who have discontinued the first medication prescribed within a year will have a relapse afterward. This shows an enormous need for developing better treatment methods and better ways to manage the disease, since current therapies do not have sufficient impact on negative symptoms, cognitive dysfunction, and compliance to treatment. In this clinical case series, we investigate the efficacy of quantitative electroencephalography (qEEG)-guided neurofeedback (NF) treatment in this population, and whether this method has an effect on concurrent medical treatment and on the patients. Fifty-one participants (25 males and 26 females) ranging from 17 to 54 years of age (mean: 28.82 years and SD: 7.94 years) were included. Signed consent was received from all patients. Most of the participants were previously diagnosed with chronic schizophrenia, and their symptoms did not improve with medication. All 51 patients were evaluated using qEEG, which was recorded at baseline and following treatment. Before recording the qEEG, participants were washed out for up to 7 half-lives of the medication. After Food and Drug Administration (FDA)-approved Nx-Link Neurometric analysis, qEEGs suggested a diagnosis of chronic schizophrenia for all participants. This was consistent with the clinical judgment of the authors. The participants’ symptoms were assessed by means of the Positive and Negative Syndrome Scale (PANSS). Besides the PANSS, 33 out of 51 participants were also evaluated by the Minnesota Multiphasic Personality Inventory (MMPI) and the Test of Variables of Attention (TOVA), both at baseline and following treatment. Each participant was prescribed an NF treatment protocol based on the results of their qEEG neurometric analysis. Each session was 60 minutes in duration, with 1 to 2 sessions per day. When 2 sessions were administered during a single day, a 30-minute rest was given between the sessions. Changes in the PANSS, MMPI, and TOVA were analyzed to evaluate the effectiveness of NF treatment. The mean number of sessions completed by the participants was 58.5 sessions within 24 to 91 days. Three dropped out of treatment between 30 and 40 sessions of NF, and one did not show any response. Of the remaining 48 participants 47 showed clinical improvement after NF treatment, based on changes in their PANSS scores. The participants who were able to take the MMPI and the TOVA showed significant improvements in these measures as well. Forty were followed up for more than 22 months, 2 for 1 year, 1 for 9 months, and 3 for between 1 and 3 months after completion of NF. Overall NF was shown to be effective. This study provides the first evidence for positive effects of NF in schizophrenia.
Nations for Mental Health Schizophrenia and Public Health. Division of Mental Health and Prevention of Substance Abuse World Health Organization, Geneva. WHO/MSA/NAM/97.6. 1998;3–9.
2.
Kane JM. Pharmacologic advances in the treatment of schizophrenia post-CATIE: an expert interview. Med Psychiatry Ment Health. 2006;11(1).
3.
JanicakPG. The CATIE study and its implications for antipsychotic drug use. Essent Psychopharmacol. 2006;7(1):53–63.
4.
GordonE. Genomics and neuromarkers are both required for the era of brain-related ‘‘Personalized Medicine’’. Brain Resource Company and The Brain Resource International Database NSW 2007, Australia. The Brain Dynamics Centre, Westmead Millennium Institute, Westmead Hospital and Western Clinical School, University of Sydney. Scientific American Reports, Special Editionon Child Development: The Early Years, 2007;17(2):76–81.
5.
SmallJG. Psychiatric disorders and EEG. In NiedermeyerELopes da SilvaF, (Eds.), Electroencephalography: Basic PrinciplesClinical Applications, and Related Fields. Baltimore, MD: Williams and Wilkins; 1993:581–596.
6.
SmallJGMilsteinVSharpleyPH. Electroecephalographic findings in relation to diagnostic constructs in psychiatry. Biol Psychiatry. 1984(19): 471–487.
7.
EllingsonRJ. The incidence of EEG abnormality among patients with mental disorders of apparently nonorganic origin: a critical review. Am J Psychiatry. 1954 (111):263–275.
8.
ShagassC. Twisted thoughts, twisted brain waves? In: ShagassCGershonSFriedhoffAJ, (Eds). Psychopathology and Brain Dysfunction. New York: Raven; 1977:353–378.
9.
ItilTM. Qualitative and quantitative EEG findings in schizophrenia. Schizophr Bull. 1977;3(1):61–79. Review.
10.
JohnERPrichepLSFridmanJEastonP.Neurometrics: Computer assisted differential diagnosis of brain dysfunctions. Science. 1988;239(4836):162–169.
11.
FentonGWFenwickPBCDollimoreJ. EEG spectral analysis in schizophrenia. Br J Psychiatry. 1980;136:445–455.
12.
KoukkouM. EEG states of the brain, information processing and schizophrenic primary symptoms. Psychiatry Res. 1982;6(2): 235–244.
13.
StevensJRLivermoreA. Telemetered EEG in schizophrenia: spectral analysis during abnormal behavior episodes. J Neurol Neurosurg Psychiatry. 1982;45:385–395.
14.
MorihisaJMDuffyFHWyattRJ. Brain electrical activity mapping (BEAM) in schizophrenic patients. Arch Gen Psychiatry. 1983;40:719–728.
15.
DierksTMaurerKIhlR. Evaluation and interpretation of topographic EEG data in schizophrenic patients. In: MauerK, ed. Topographic Brain Mapping of EEG and Evoked Potentials. Berlin, Heidelberg: Springer-Verlag; 1989:507–517.
16.
MerrinELFloydTC. Negative symptoms and EEG alpha activity in schizophrenic patients. Schizophr Res. 1992;8(1):11–20.
17.
ColomboCGambiniOMacciardiF. Alpha reactivity in schizophrenia and in schizophrenic spectrum disorders: demographic, clinical and hemispheric assessment. Int J Psychophysiol.
1989;7:47–54.
18.
LaurianSBryoisCGaillardJM. Some aspects of brain electrical activity in schizophrenia. Adv Biol Psychiatry. 1984;15:60–68.
19.
KemaliDMajMGalderisiS. Clinical, biological, and neuropsychological features associated with lateral ventricular enlargement in DSM III schizophrenic disorder. Psychiatry Res. 1986;21(2):137–149.
20.
KarsonCNCoppolaRDanielDG. Alpha frequency in schizophrenia: an association with enlarged cerebral ventricles. Am J Psychiatry. 1988;145:861–864.
21.
GalderisiSMajMMucciA. QEEG alpha1 changes after a single dose of high-potency neuroleptics as a predictor of short-term response to treatment in schizophrenia patients. Biol Psychiatry. 1994;35:367–374.
22.
GattazWFMayerSZieglerP. Hypofrontality on topographic EEG in schizophrenia: correlations with neuropsychological and psychopathological parameters. Eur Arch Psychiatry Clin Neurosci. 1992;241:328–332.
23.
JohnERPrichepLSAlperKR. Quantitative electrophysiological characteristics and subtyping of schizophrenia. Biol Psychiatry. 1994;36:801–826.
CzoborPVolovkaJ. Quantitative EEG electroencephalogram effect of Risperidone in schizophrenic patients. J Clin Pharmacol. 1993;13:332–342.
26.
GuntherWBreitlineD. Predominant sensorimotor area left hemisphere dysfunction in schizophrenia measured by brain electrical activity mapping. Biol Psychiatry. 1985;20:515–532.
27.
ShagassCRoemerR. Evoked potential topography in unmedicated and medicated schizophrenics. Int J Psychophysiol. 1991;10:213–224.
28.
NagaseYOkuboYMatsuuraMKojimaTToruM. EEG coherence in unmedicated schizophrenic patients: topographical study of predominantly never medicated cases. Biol Psychiatry. 1992;32:1028–1034.
29.
WellerMMontaguJD. EEG coherence in schizophrenia: a preliminary study. Electroencephalogr Clin Neurophysiol. 1980;49: 100–101.
30.
SaletuBKufferleBGrünbergerJFöldesPTopitzAAndererP. Clinical, EEG mapping and psychometric studies in negative schizophrenia: Comparative and psychometric trials with amisulpride and fluphenazine. Neuropsychobiology. 1994;19(3):125–135.
31.
SchellenbergRMilchWSchwarzASchoberFDimpfelW. Quantitative EEG and BPRS data following haldol-decanoate administration in schizophrenics. Int Clin Psychopharmacol. 1994;9(1):17–24.
32.
FordMRGoetheJWDekkerDK. EEG coherence and power in the discrimination of psychiatric disorders and medication effects. Biol Psychiatry. 1986;21(12):1175–1188.
33.
MerrinELFloyTCFeinG. EEG Coherence in unmedicated schizophrenic patients. Biol Psychiatry. 1989;25(1):60–66.
34.
PrichepLS, John ER. qEEG profiles of psychiatric disorders. Brain Topogr. 1992;4(4):249–257.
35.
ItilTMShapiroDMHerrmannWMSchulzWMorganV. HZI systems for EEG parametrization and classification of psychotropic drugs. Pharmakopsychiatr Neuropsychopharmakol. 1979; 12(1):4–19.
36.
ItilTMFreyhanFABanJH, eds. Psychotropic Drugs and theHuman EEG. New York, NY: Karger, S. Inc; 1974.
37.
CogerRWDymondAMSerafetinidesEA. Electroencephalographic similarities between chronic alcoholics and chronic, non-paranoid schizophrenics. Arch GenPsychiatry. 1979;36:91–94.
38.
GalderisiSMucciAMignoneML. QEEG mapping in drug-free schizophrenics: differences from healthy subjects and changes induced by haloperidol treatment. Schizoph Res. 1992;6:15–24.
39.
LifshitzKLeeKLSussweinS. Long-term replicability of EEG spectra and auditory evoked potentials in schizophrenic and normal subjects. Neuropsychobiol.
1987;18:205–211.
40.
OmoriMKoshinoYMurataT. Quantitative EEG in never-treated schizophrenic patients. Biol Psychiatry. 1995;38(5):305–309.
41.
MerrinELFloydTC. Negative symptoms and EEG alpha in schizophrenia: a replication. Schizophr Res. 1996;19:151–161.
JinYPotkinSGSandmanCABunneyWEJr. Electroencephalographic photic driving in patients with schizophrenia and depression. Biol Psychiatry. 1997;15;41(4):496–499.
44.
LubarJF. Discourse on the development of EEG diagnostics and biofeedback for attention-deficit/hyperactivity disorders. Biofeedback Self Regul. 1991;16(3):201–225.
45.
ThompsonLThompsonM. Neurofeedback combined with training in metacognitive strategies: effectiveness in students with ADD. Appl PsychophysiolBiofeedback. 1998;23(4):243–263.
46.
KandelER. The molecular biology of memory storage: a dialogue between genes and synapses. Science. 2001;294:1030–1038.
47.
ArnsMde RidderSStrehlUBretelerMCoenenA. Efficacy of neurofeedback treatment in ADHD: the effects on inattention, impulsivity and hyperactivity: a meta-analysis. Clin EEG Neurosci. 2009;40(3):180–189.
48.
ShouseMNLubarJF. Operant conditioning of EEG rhythms and ritalin in the treatment of hyperkinesis. Biofeedback Self Regul. 1979;4(4):299–312.
49.
ShouseMNLubarJF. Physiological basis of hyperkinesis treated with methylphenidate. Pediatrics. 1978;62(3):343–351.
50.
TanGThornbyJHammondDC. Meta-analysis of EEG biofeedback in treating epilepsy. Clin EEG Neurosci. 2009;40(3):173–179.
51.
OthmerSOthmerSFMarks CS. EEG biofeedback training for attention deficit disorder, specific learning disabilities, and associated conduct problems. J Biofeedback Soc California. 1992;7(4):24–27.
52.
ThorntonKECarmodyDP. Electroencephalogram biofeedback for reading disability and traumatic brain injury. Child Adolesc Psychiatr Clin N Am. 2005;14(1):137–162, vii. Review.
53.
FernandezTHerreraWHarmonyT. EEG and behavioral changes following neurofeedback treatment in learning disabled children. Clinical Electroecephalography. 2003;34(3):145–150.
54.
BretelerMHMArnsMPetersSGiepmansIVerhoevenL. Improvements in spelling after QEEG-based neurofeedback in dyslexia: a randomized controlled treatment study. Appl Psychophysiol Biofeedback. 2010;35(1):5–11.
55.
ScottWKaiserD. Augmenting chemical dependency treatment with neurofeedback training. J Neurotherapy, 1998;3(1):66.
56.
TrudeauDL. A review of the treatment of addictive disorders by EEG biofeedback. Clin Electroencephalogr. 2000;31(1):13–26.
57.
ScottWCBrodTMSideroffSKaiserDSagaM. Type-specific EEG biofeedback improves residential substance abuse treatment. Presented at the American Psychiatric Association Annual Meeting; 2002. http://eegbiofeedback.com/research.html. Accessed June 19, 2010.
58.
BaehrERosenfeldJPBaehrR. The clinical use of an alpha symmetry protocol in the neurofeedback treatment of depression: two case studies. J Neurotherapy. 1997;2(3):10–23.
59.
BaehrERosenfeldJPBaehrR. The clinical use of an alpha symmetry protocol in the neurofeedback treatment of depression: follow-up study one to five years post therapy. J Neurotherapy. 2001;4(4):11–18.
60.
RosenfeldJP. An EEG biofeedback protocol for affective disorders. Clin Electroencephalogr. 2000;31(1):7–12.
61.
HammondDC. Neurofeedback with anxiety and affective disorders. Child AdolescPsychiatr Clin N Am2005;14(1):105–123, vii.
62.
RaymondJVarneyCParkinsonLAGruzelierJH. The effects of alpha/theta neurofeedback on personality and mood. Cogn Brain Res.
2005;23(2-3):287–292.
63.
SurmeliTErtemA. QEEG guided neurofeedback therapy in personality disorders: 13 case studies. Clin EEG Neurosci. 2009; 40(1):5–10.
64.
StermanMB. Physiological origins and functional correlates of EEG rhythmic activities: implications for self-regulation. Biofeedback Self Regul. 1996;21(1):3–33.
65.
ThatcherRW. Normative EEG databases and Biofeedback. J Neurotherapy. 1998;2(4):8–39.
DuffJ. The usefulness of QEEG and neurotherapy in the assessment and treatment of post-concussion syndrome. Clin EEG Neurosci. 2004;35(4).
68.
SurmeliTErtemA. Efficacy of QEEG and neurofeedback in the assessment and treatment of post concussive syndrome: 24 Cases. Oral Presentation, ISNR Meeting; 2007.
69.
SchneiderFRockstrohBHeimannH. Self-regulation of slow cortical potentials in psychiatric patients: schizophrenia. Biofeedback Self Regul. 1992;17(4):277–292.
70.
GruzelierJHardmanEWildJZamanR. Learned control of slow potential interhemispheric asymmetry in schizophrenia. Int J Psychophysiol. 1999;34(3):341–348.
71.
GruzelierJ. Self regulation of electrocortical activity in schizophrenia and schizotypy: a review. Clin Electroencephalogr. 2000;31(1):23–29. Review.
72.
CortoosAVerstraetenECluydtsR. Neurophysiological aspects of primary insomnia: implications for its treatment. Sleep Med Rev. 2006;10(4):255–266. Epub June 27, 2006.
SchwartzMSPharrOMCourseyRD. The use of and utility of EMG biofeedback with chronic schizophrenic patients. Biofeedback Self Regul. 1989;143:229–245.
75.
SchwartzMS. Biofeedback: A Practitioner’s Guide2nd ed. 1995; Guilford Press, New York.
76.
HoffmanREHawkinsKAGueorguievaR. Transcranial magnetic stimulation of left temporoparietal cortex and medication-resistant auditory hallucinations. Arch Gen Psychiatry. 2003;60(1):49–56.
77.
d'AlfonsoAAAlemanAKesselsRP. Transcranial magnetic stimulation of left auditory cortex in patients with schizophrenia: effects on hallucinations and neurocognition. J Neuropsychiat Clin Neurosci. 2002;14(1):77–79.
78.
RollnikJDHuberTJMogkH. High frequency repetitive transcranial magnetic stimulation (rTMS) of the dorsolateral prefrontal cortex in schizophrenic patients. Neuroreport. 2000;11(18):4013–4015.
79.
ChoiSWChiSEChungSYKimJWAhnCYKimHT. Is alpha wave neurofeedback effective with randomized clinical trials in depression? A pilot study. Neuropsychobiology. 2011;63:43–51.
80.
PrischepLSJohnER. Neurometrics: Clinical applications. In: Lopes da SilvaFHStorm van LeeuwenWRemondA, Eds., Clinical Applications of Computer Analysis of EEG and otherNeurophysiological Variables. Handbook of Electroencephaloand Clinical Neurophysiology. Vol 2. Amsterdam, The Netherlands: Elsevier; 1986:153–170.
81.
FisherS. FPO2 and the regulation of fear. ISNR J Newsletter. 2006;15:117.
82.
RadulescuARRubinDStreyHHMujica-ParodiLR. Power spectrum scale invariance identifies prefrontal dysregulation in paranoid schizophrenia. Human Brain Mapping. 2011;May 12. doi: 10.1002/hbm.21309. [Epub ahead of print]
83.
DeanBKeriakousDScarrEThomasEA. Gene expression profiling in Brodmann's area 46 from subjects with schizophrenia. Australian New Zealand J Psychiatry. 2007; 41:4:308–320.
84.
WilliamsLMDasPHarrisAW. Dysregulation of arousal and amygdala-prefrontal systems in paranoid schizophrenia. Am J Psychiatry. 2004;161:480–489.
85.
Mujica-ParodiLRCorcoranCGreenbergTSackeimHAMalaspinaD. Are cognitive symptoms of schizophrenia mediated by abnormalities in emotional arousal?CNS Spectr. 2002;7:58–60, 65–69.
86.
RaglandJDLairdARRanganathCBlumenfeldRSGonzalesSMGlahnDC. Prefrontal activation deficits during episodic memory in schizophrenia. Am J Psychiatry. 2009;166:863–874.
87.
YoonJHMinzenbergMJUrsuS. Prefrontal cortex dysfunction is associated with disrupted coordinated brain activity in schizophrenia: relationship to impaired cognition, behavioral disorganization and global function. Am J Psychiatry. 2008;165:1006–1014.
88.
FlorescoSBTseMT. Dopaminergic regulation of inhibitory and excitatory transmission in the basolateral amygdala-prefrontal cortical pathway. J Neurosci. 2007;27:2045–2057.
89.
LeDouxJ. The emotional brain, fear, and the amygdala. Cell Mol Neurobiol. 2003;23:727–738.
90.
PhelpsEADelgadoMRNearingKILeDouxJE. Extinction learning in humans: role of the amygdala and vmPFC. Neuron. 2004;43:897–905.
91.
RosenkranzJAMooreHGraceAA. The prefrontal cortex regulates lateral amygdala neuronal plasticity and responses to previously conditioned stimuli. J Neurosci. 2003;23:11054–11064.
92.
LawrieSMBuechelSWhalleyHC. Reduced frontotemporal functional connectivity in schizophrenia associated with auditory hallucinations. Biol Psychiatry. 2002;51:1008–1011.
93.
BurnsJJopDBastinME. Structural disconnectivity in schizophrenia: a diffusion tensormagnetic resonance imaging study. Br J Psychiatry. 2003;182:439–443.
94.
BaerwaldJPTryonWWSandfordJ. Bimodal response sensitivity and bias in a test of sustained attention contrasting patients with schizophrenia and bipolar disorder to normal comparison group. Arch Clin Neuropsychol. 2005;20(1):17–32.
95.
LiebermanJAStroupTSMcEvoyJP. The clinical antipsychotic trials of intervention effectiveness (CATIE) investigators, effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med. 2005;353:1209–1223.
96.
WaltersGD. The MMPI and schizophrenia: a review. Schizophr Bull 1983;9(2):226-246. Review. Holland TR, Levi M, Watson CG. MMPI basic scales vs. two-point codes in the discrimination of psychopathological groups. J Clin Psychology. 1981;37:394–396.
97.
CoburnKLLauterbachECBoutrosNNArchiniegasDCoffeyCE. The value of quantitative electroencephalography in clinical psychiatry: A report by the Committee on Research of the American Neuropsychiatric Association. J Neuropsychiatry Clin Neurosci. 2006;18:4.
98.
KnottVMahoneyCKennedySEvansS. EEG power, frequency, asymmetry and coherence in male depression. Psychiatry Research: Neuroimaging. 2001;106(2):123–140.
99.
ThatcherRWNorthDMBiverCJ. Development of cortical connections as measured by EEG coherence and phase delays. Human Brain Mapping. 2008;29(12):1400–1415.
100.
ThatcherRWNorthDBiverC. EEG and intelligence: relations between EEG coherence, EEG phase delay and power. Clin Neurophysiol. 2005;116(9):2129–2141.
101.
AbarbanelA. Gates, states, rhythms, and resonances: the scientific basis of neurofeedback training. J Neurotherapy. 1995;1(2):15–38.
102.
SurmeliTErtemA. Obsessive compulsive disorder and the efficacy of qEEG-guided neurofeedback treatment: a case series. Clin EEG Neurosci. 2011;42:195–201.
103.
RuizSSangkyunLSoekadarSR. Acquired self-control of insula cortex modulates emotion recognition and brain network connectivity in schizophrenia. Human Brain Mapping. 2011. doi: 10.1002/hbm.21427.
104.
From Discovery To Cure. Accelerating the Development of New and Personalized Interventions for Mental Illness. Report of the National Advisory Mental Health Council’s Workgroup. August 2010.
